Melody Noel Brown

Array ( [id] => 16793284 [patent_doc_number] => 20210123101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => MIRNA MARKER AND KIT ASSOCIATED WITH POSTMENOPAUSAL OSTEOPOROSIS [patent_app_type] => utility [patent_app_number] => 16/617370 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12119109 [patent_doc_number] => 20180002696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA' [patent_app_type] => utility [patent_app_number] => 15/689713 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 41038 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15689713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13690071 [patent_doc_number] => 20170355990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA [patent_app_type] => utility [patent_app_number] => 15/689754 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37262 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15689754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12119167 [patent_doc_number] => 20180002754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'FRIZZLED 2 AS A TARGET FOR THERAPEUTIC ANTIBODIES IN THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/673848 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 19265 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15673848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297489 [patent_doc_number] => 20180200281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => CONTROL OF COLEOPTERAN PESTS USING RNA MOLECULES [patent_app_type] => utility [patent_app_number] => 15/746449 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058983 [patent_doc_number] => 20170335327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS' [patent_app_type] => utility [patent_app_number] => 15/650297 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 22045 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15355999 [patent_doc_number] => 10526602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Segmented micro RNA mimetics [patent_app_type] => utility [patent_app_number] => 15/648288 [patent_app_country] => US [patent_app_date] => 2017-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 37 [patent_no_of_words] => 38910 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15648288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15194299 [patent_doc_number] => 10494631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => siRNA compounds comprising terminal substitutions [patent_app_type] => utility [patent_app_number] => 15/642581 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23881 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15642581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15356003 [patent_doc_number] => 10526604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Modulation of nuclear-retained RNA [patent_app_type] => utility [patent_app_number] => 15/642709 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 32265 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15642709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567511 [patent_doc_number] => 20190211362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => MATERIALS AND METHODS FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (DM1) AND OTHER RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/312651 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624498 [patent_doc_number] => 20180099996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => FUNCTIONAL LIGANDS TO PHTHATATES [patent_app_type] => utility [patent_app_number] => 15/634926 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15634926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12999879 [patent_doc_number] => 10023597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => RNA interference agents for p21 gene modulation [patent_app_type] => utility [patent_app_number] => 15/634771 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8226 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15634771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13703361 [patent_doc_number] => 20170362635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => MUSCLE-SPECIFIC CRISPR/CAS9 EDITING OF GENES [patent_app_type] => utility [patent_app_number] => 15/628533 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000193 [patent_doc_number] => 20170304348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'MiRNA and its Diagnostic and Therapeutic Uses in Diseases or Conditions Associated with Melanoma, or in Diseases or Conditions Associated with Activated BRAF Pathway' [patent_app_type] => utility [patent_app_number] => 15/625945 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 51537 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15625945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435765 [patent_doc_number] => 20190175754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => METHODS FOR TREATING SUBJECTS SUFFERING FROM ACUTE MYELOID LEUKEMIA WITH FLT3 LIGAND-TARGETED MIR-150 NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 16/310104 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12119110 [patent_doc_number] => 20180002693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'COMPOSITIONS AND METHODS' [patent_app_type] => utility [patent_app_number] => 15/618365 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101807 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026815 [patent_doc_number] => 10036024 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) [patent_app_type] => utility [patent_app_number] => 15/614147 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 12704 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403739 [patent_doc_number] => 20190167713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => Medicament for the Treatment of Acute Liver Failure [patent_app_type] => utility [patent_app_number] => 16/302502 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15088931 [patent_doc_number] => 20190339276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => Application of ERH Gene in the Preparation of Bladder Cancer Diagnosis and Treatment Products [patent_app_type] => utility [patent_app_number] => 16/090658 [patent_app_country] => US [patent_app_date] => 2017-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16090658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641940 [patent_doc_number] => 20180105811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 15/604335 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15604335 [rel_patent_id] =>[rel_patent_doc_number] =>)